1. Field of the Invention
The present invention relates generally to medical devices and methods. More particularly, the present invention relates to apparatus and methods for delivering a plurality of separate luminal prostheses within a body lumen, such as a blood vessel.
Coronary artery disease is the leading cause of death and morbidity in the United States and Western society. In particular, atherosclerosis in the coronary arteries can cause myocardial infarction, commonly referred to as a heart attack, which can be immediately fatal or, even if survived, can cause damage to the heart which can incapacitate the patient.
While coronary artery bypass surgery can be an effective treatment for stenosed arteries resulting from atherosclerosis or other causes, it is a highly invasive procedure which is also expensive and which requires substantial hospital and recovery time. Percutaneous transluminal angioplasty, commonly referred to as balloon angioplasty, is less invasive, less traumatic, and significantly less expensive than bypass surgery. Heretofore, however, balloon angioplasty has not been considered as effective a treatment as bypass surgery. The effectiveness of balloon angioplasty, however, has improved significantly with the introduction of stenting, which involves the placement of a scaffold structure within an artery that has been treated by balloon angioplasty. The stent inhibits abrupt reclosure of the artery and has some benefit in inhibiting subsequent restenosis resulting from hyperplasia.
Presently available stents may be generally categorized as either “closed cell configurations” or “open cell configurations.” Closed cell configurations are characterized by ellipses, ovals, and polygonal structures, such as closed boxes, rhomboids, diamonds, and the like, which open in the circumferential direction and shorten in the axial direction as the stent is expanded. Open cell configurations include zigzag and serpentine structures which may be formed as a plurality of discreet rings or may be formed from a single continuous wire or other element. Closed cell stents are advantageous in that they provide better coverage of the blood vessel wall when the stent is deployed. This is particularly advantageous in tightly curved segments of the vasculature where even stent coverage in both the axial and circumferential directions on the outer wall of the vessel has been shown to reduce restenosis. Such even coverage is also an advantage in achieving uniform delivery from drug eluting stents. In contrast, open cell stent configurations are generally more flexible than the closed cell configurations. Such flexibility is advantageous in the tortuous regions of the vasculature where enhanced flexibility can provide better conformance to the vessel being treated. Better conformance can reduce the stress on the vessel wall, particularly at the stent ends, and lead to reduced restenosis.
For these reasons, it would be desirable to provide improved stents and stent structures. In particular, it would be desirable to provide stents and stent structures which combine the improved wall coverage of closed cell stent structures with the increased flexibility of open cell stent structures. It would be still further desirable if such improved stent structures allowed a physician to optimize the length of vessel being treated in accordance with the nature of the disease, allowed for the delivery of both very short and very long stent structures, and optionally permited delivery of stent structures at multiple contiguous and/or non-contiguous locations within a body lumen. At least some of these objectives will be met by the inventions described hereinafter.
2. Description of the Background Art
U.S. Pat. Nos. 6,200,337 and 5,870,381 describe stents having closed cell rings with overlapping portions connected by axial connecting members. U.S. Pat. No. 6,375,676 describes a stent having open cell rings with overlapping portions connected by axial connecting members. U.S. Patent Application Publication Nos. 2002/0188343 and 2002/0188347 describe expandable stents having interconnecting elements which interlock circumferentially adjacent bridges between axially adjacent stent segments. U.S. Pat. No. 4,580,568 describes the sequential placement of a plurality of zigzag ring stents where the stents may optionally be overlapped (
The present invention provides methods and apparatus for prosthesis placement, such as stenting of body lumens, typically blood vessels, and more typically coronary arteries. The methods and systems will also find significant use in the peripheral vasculature, the cerebral vasculature, and in other ducts, such as the biliary duct, the fallopian tubes, and the like. The terms “stent” and “stenting” are defined to include any of the wide variety of expandable prostheses and scaffolds which are designed to be intraluminally introduced to a treatment site and expanded in situ to apply a radially outward force against the inner wall of the body lumen at that site. The stents and prostheses of the present invention commonly comprise a closed or, less preferably, an open lattice structure, and are typically formed from a malleable or elastic metal. When formed from a malleable metal, such as stainless steel, gold, platinum, titanium, and super alloys, the stents will typically be expanded by a balloon which causes plastic deformation of the lattice so that it remains opened after deployment. When formed from an elastic metal, including super elastic metals such as nickel-titanium alloys, the lattice structures will usually be radially constrained when delivered and deployed by releasing the structures from such radial constraint so that they “self-expand” at the target site. When the stent or lattice structures are covered with a fabric or polymeric membrane covering, they are commonly referred to as grafts. Grafts may be used for the treatment of aneurysms or other conditions which require placement of a non-permeable or semi-permeable barrier at the treatment site. The terms “stent” and “stent structures” refer broadly to all radially expansible stents, grafts, and other scaffold-like structures which are intended for deployment within body lumens.
The stents and stent structures of the present invention may have any of a variety of common constructions, including closed cell constructions such as expansible ovals, ellipses, box structures, expandable diamond structures, expandable rhomboid structures, as well as other regular and irregular polygonal structures, etc. In addition, the closed cells may have complex slotted geometries, such as H-shaped slots, I-shaped slots, J-shaped slots, etc. Suitable open cell structures include zigzag structures, serpentine structures, and the like. Such conventional stent structures are well described in the patent and medical literature. Specific examples of suitable stent structures are described in the following U.S. Patents, the full disclosures of which are incorporated herein by reference: U.S. Pat. Nos. 6,315,794; 5,980,552; 5,836,964; 5,527,354; 5,421,955; 4,886,062; and 4,776,337. Preferred structures are described herein with reference to
According to one aspect of the present invention, stents will comprise a plurality of independent expansible rings each having a length of 1 mm or greater, usually 2 mm or greater, and sometimes of 3 mm or greater, usually being in the range from 1 mm to 10 mm, typically from 2 mm to 7 mm, more typically from 2 mm to 5 mm. The use of such short ring lengths is advantageous since the overall stent length will be a multiple of the ring length.
The methods and apparatus of the present invention will provide for the deployment of a plurality of stents or other prostheses from a common stent delivery catheter. Usually, the number of delivered stents will be in the range from 2 to 50, typically from 3 to 30, and most typically from 3 to 25. As more stents are placed on the delivery catheter, the individual stent length will often be somewhat less, although this is not necessarily the case in all instances. The multiple prostheses may be deployed individually or in groups of two or more at a single location or at multiple spaced-apart locations in the body lumen or lumens.
In another aspect of the present invention, stent structures will comprise a plurality of radially expansible rings, as generally described above, arranged along an axial line. Expansible rings are arranged adjacent to each other and will include axially extending elements which interleave or nest with similarly axially extending elements on adjacent rings. By “interleaved” it is meant that the axially extending elements on adjacent rings will interpenetrate with each other in an axial direction, at least prior to stent expansion and preferably even after stent expansion. Usually, the interpenetrating elements will not overlap, i.e., be positioned one over another in the radial direction, but it is possible that in some implementations there may be some overlapping prior to or even after expansion. The axial interpenetration will be at least 0.1 mm, usually being at least 1 mm, and often being in the range from 1 mm to 5 mm, and will of course depend on the axial length(s) of the adjacent ring(s). Expressed as a percentage, the axial length of the axially extending elements will usually be at least 5% of the axial length of the ring, usually being from 5% to 50%, and preferably being from 20% to 30%.
Preferably, the axially extending elements on adjacent rings will interleave without interlocking so as to permit axial separation between the adjacent rings prior to expansion of the rings. However, axially extending elements may, in some instances, also interpenetrate in a peripheral direction prior to expansion. Such peripheral interpenetration can provide axial interlocking of the axially adjacent expansible rings prior to expansion. It will usually be desirable or even necessary that the peripheral interpenetration be relieved during radial expansion of the stent structures so that the independent rings be released from each other when deployed. In other instances, however, a tether or other types of links may be provided to interconnect or otherwise restrain the rings even after expansion and deployment.
It is not necessary that all adjacent rings be unconnected, although at least two, and preferably three, four, five, eight, ten, or more adjacent rings will be unconnected. Thus, some (but fewer than all) of the adjacent rings of the stent structures may have ties or links therebetween, including flexible or non-flexible (deflectable) ties or links. The axially adjacent rings, however, will usually not be connected, although in some cases they may have easily separable or non-permanent connections as described in more detail below. Each expansible ring will preferably comprise expansible closed cell structures, as set forth above. Less preferably, the expansible rings may comprise expansible open cell structures, as set forth above. The lengths and diameters of the individual rings have been set forth generally above. The stent structure will typically comprise from 2 to 50 individual rings, usually from 3 to 30 individual rings, and often from 3 to 25 individual rings.
The spacing between adjacent rings may be uniform or non-uniform, preferably being uniform. In some cases, it is desirable that the edges of the adjacent rings be spaced-apart by a uniform distance in the axial direction, typically at least 0.1 mm, usually being from 0.1 mm to 0.5 mm, prior to stent expansion. In other situations, it will be preferred that the adjacent rings be in contact with each other at discreet points or along continuous sections of the edges. In some cases, the stent structures will be configured to shorten upon expansion to increase the spacing between rings. It is usually preferable that the edges of the adjacent rings not overlap, at least prior to deployment. Deployment of the stents, particularly in curved and tortuous luminal regions, may sometimes result in touching and overlapping of the stent rings.
The stent structures may be modified in a variety of ways which are used with other conventional stents. For example, some or all of the radially expansible rings may releasably carry a biologically active agent, such as an agent which inhibits hyperplasia. Exemplary anti-hyperplasia agents include anti-neoplastic drugs, such as paclitaxel, methotrexate, and batimastal; antibiotics such as doxycycline, tetracycline, rapamycin, everolimus and other analogs and derivatives of rapamycin, and actinomycin; amino suppressants such as dexamethasone and methyl prednisolone; nitric oxide sources such as nitroprussides; estrogen; estradiols; and the like.
In another aspect of the present invention, a stent deployment system comprises an elongate carrier having a central axis and including a plurality of radially expansible rings arranged over a surface thereof. At least some of the radially expansible rings will have the features and characteristics just described with respect to the present invention. The elongate carriers of the stent deployment systems will typically comprise a radially expansible balloon having an outer surface where the radially expansible rings are disposed over the outer surface of the balloon. In such cases, the balloon may comprise a single inflation chamber in which case all of the rings will be expanded simultaneously. Alternatively, the balloon may comprise a plurality of independently inflatable chambers so that individual expansible rings may be deployed separately from the other rings.
The elongated carrier of the stent deployment system may alternatively comprise a carrier tube having an inner surface which carries and constrains the radially expansible rings. In such cases, the expansible rings will usually be self-expanding, i.e., held in a radially constrained configuration by the carrier tube prior to release and expansion at a luminal target site. Usually, the carrier tube structures will further comprise a pusher tube arranged to axially advance the radially expansible rings from the carrier tube. The elongated carrier may still further comprise a balloon arranged to receive and expand individual rings as they advance from the carrier tube, in which case the carrier may be used for delivering the formable (balloon-expansible) stent structures. However, such a balloon may also be used with self-expanding stent structures to control or enhance expansion, to perform predilatation of a lesion prior to stent deployment, or to further expand the stent structures and dilate the vessel lumen after the structures have self-expanded.
In a further aspect of the present invention, multiple independent stent rings are arranged on a carrier by the following methods. An elongated carrier structure is provided and a plurality of radially expansible rings comprising axially extending elements are mounted on the carrier structure such that the axially extending elements on adjacent rings interleave or nest after they are mounted. The number of rings mounted on the carrier is selected to provide a desired overall stent length, and the number of rings is typically in the ranges set forth above, providing overall stent lengths in the range from 6 mm to 120 mm, usually from 9 mm to 100 mm, and typically from 12 mm to 50 mm. Other aspects of the individual radially expansible rings have been described above.
In yet another aspect of the present invention, methods for stenting a body lumen comprise delivering to the body lumen a stent structure having a plurality of radially expansible rings. The rings are as described above with respect to other aspects of the present invention, and at least some of the rings are expanded within the body lumen so that the axially extending elements open and axially move apart from each other as they radially expand. Preferably, the length of the axially extending elements and degree of radial expansion will be selected so that the elements remain interleaved even after being fully expanded within the body lumen. Such an interleaving structure enhances the continuity of lumenal wall coverage provided by the deployed stent structure. Target body lumens are typically blood vessels, more typically arteries, such as coronary arteries. The rings may be delivered simultaneously, typically using a single inflatable balloon, or sequentially, typically using a carrier tube, pusher tube and optionally deployment balloon. Methods may be used for delivering from 3 to 50 rings, usually from 3 to 30 rings, and typically from 3 to 25 rings, to cover a luminal length in the range from 6 mm to 120 mm, usually from 9 mm to 100 mm, and typically from 12 mm to 50 mm.
The present invention provides apparatus, systems, and methods for preparing and delivering stent structures comprising a plurality of “separate” or “discreet” radially expansible ring segments. By “separate” or “discreet,” it is meant that the ring segments are unconnected (or easily disconnected) at the time they are delivered to a target body lumen. Usually, the ring segments will be closely packed to provide a relatively high degree of vessel wall coverage after they are expanded. By disconnecting the adjacent segments, however, such a tightly packed structured can retain a very high degree of flexibility permitting delivery and conformance in even highly torturous regions of the vasculature and other body lumens.
The ability to closely pack the expansible ring segments and achieve a high degree of vessel wall coverage is achieved at least partly because at least some of the axially adjacent rings comprise axially extending elements which interleave or nest with axially extending elements on an adjacent connected ring. Usually, the axially extending elements will be formed from a radially expansible portion of the ring, e.g., the element will be part of the closed cell structure or open cell structure as described in more detail hereinbelow. As these expansible sections will typically foreshorten as they are radially expanded, interleaving and nesting the segments on adjacent rings prior to expansion minimizes or preferably eliminates any gaps in coverage after the stent is expanded, as described in more detail below.
The stent structures of the present invention may be fabricated as either balloon-expansible or self-expanding stents according to methods well known in the art. Typical deformable materials suitable for fabricating balloon-expansible stent structures include 316L stainless steel, gold, platinum, cobalt chrome, platinum, and the like. Suitable resilient materials for self-expanding stents include nickel titanium alloys, various spring stainless steel alloys, Eligloy® alloy, and the like. It will also be possible to form the stent structures of the present invention from both natural and synthetic polymers. Natural polymers include collagen, gelatin, chitin, cellulose, and the like. Suitable synthetic polymers include polyglycolic acids (PGA), polylactic acids (PLA), poly ethylene glycols (PEG), polyamides, polyimides, polyesters, and the like. In some instances, it would be possible to form different radially expansible segments from different materials in order to achieve different properties.
The stent structures will comprise a plurality of the individual radially expansible ring segments with typical dimensions, numbers, and the like, described above in the summary. The plurality of ring segments will be arranged prior to delivery, in a manner suitable for delivery to and deployment within a target blood vessel or other body lumen. Usually, the plurality of radially expansible rings will be arranged along an axial line, typically defined by a deployment balloon, a delivery tube, or some combination thereof. The expansible ring segments will be arranged so that the axially extending elements on each of the segments is interleaved with corresponding axial extending elements on adjacent but unconnected ring segments. Referring now to
In
Of particular importance to the present invention,
The advantages of the present invention are particularly apparent in curved blood vessels BV, as illustrated in
A similar result can be achieved with a stent structure 20 comprising a plurality of open cell zigzag ring structures 22, shown in
Referring now to
Axial separation of the rings 32 of stent structure 30 can be inhibited by modifying the ring geometries in a variety of ways, such as shown in
Referring now to
Referring now to
Stent structures comprising multiple rings 50 are shown in their unexpanded and expanded configuration in
Ring structure 60 of
Ring structure 70 in
Ring structure 80 of
As illustrated thus far, the stent structures have generally maximized to vessel wall coverage achieved after expansion. While this will often be desired, in some instances it may be desired to lessen the amount of wall coverage. The stent structures shown in
In
Stent structure 96 (
Stent structures according to the present invention may be delivered in a variety of ways. As illustrated in
Referring now to
Referring now to
Referring now to
A further alternative stent structure according to the invention is illustrated in
Stent segment 201 is configured to interleave with an adjacent stent segment of similar construction. Upper and lower axial struts 206A, 206B and outer ends 208 form axial elements E that are received in the spaces S between each element E of the adjacent stent segment 201.
In a preferred embodiment, a spacing member 212 extends outwardly in the axial direction from a selected number of outer circumferential struts 209 and/or connecting struts 213. Spacing member 212 preferably itself forms a subcell 214 in its interior, but alternatively may be solid without any cell or opening therein. For those spacing members 212 attached to outer circumferential struts 209, subcell 214 preferably communicates with I-shaped cell 205. Spacing members 212 are configured to engage the curved outer ends 208 of an adjacent stent segment 201 so as to maintain appropriate spacing between adjacent stent segments. In one embodiment, spacing members 212 have outer ends 216 with two spaced-apart protrusions 218 that provide a cradle-like structure to index and stabilize the curved outer end 208 of the adjacent stent segment. Preferably, spacing members 212 have an axial length of at least about 10%, more preferably at least about 25%, of the long dimension L of I-shaped cells 205, so that the I-shaped cells 205 of adjacent stent segments are spaced apart at least that distance. This results in elements E interleaving a distance of at least about 10%, preferably at least about 25%, and more preferably at least about 50% of their axial length as measured from the circumferential connecting struts 213. Because spacing members 212 experience little or no axial shortening during expansion of stent segments 201, this minimum spacing between stent segments is maintained both in the unexpanded and expanded configurations.
As an additional feature, circumferential slots 204 provide a pathway through which vessel side branches can be accessed for catheter interventions. Should stent segment 201 be deployed at a location in which it covers the ostium of a side branch to which access is desired, a balloon dilatation catheter may be positioned through circumferential slot 204 and expanded. This deforms circumferential struts 209, 211 axially outward, thereby expanding circumferential slot 204 and further expanding upper and lower slots 207, as shown in phantom in
One of the differences between the embodiment of
In a preferred embodiment, stent segments 201′ retain some degree of interleaving in the expanded configuration, with outer ends 234 of elements E on adjacent stent segments being at least circumferentially aligned with each other, and preferably extending into spaces S of the adjacent stent segment a distance of at least about 1%, more preferably at least about 5%, and in some cases at least about 10% of the axial length of elements E as measured from circumferential connecting struts 242. In one exemplary embodiment, for a stent segment 201′ having an axial length of 4 mm and an unexpanded diameter of about 0.5-1.5 mm, elements E have an axial length of about 1 mm and are interleaved a distance Du of about 0.1-0.5 mm in the unexpanded configuration. Segments 201′ are expandable to a diameter of 2.5-3.5 mm and elements E are interleaved a distance De of about 0.01-0.1 mm in the expanded configuration.
It should also be noted that the embodiment of
As shown in
The stent structures of the invention are preferably radiopaque so as to be visible by means of fluoroscopy. Radiopaque markers and/or materials may be used in or on the stent structures. Markers of radiopaque materials may be applied to the exterior of the stents, e.g, by applying a metal such as gold, platinum, a radiopaque polymer, or other suitable coating or mark on all or a portion of the stents. Alternatively, the stent structures may include a radiopaque cladding or coating or may be composed of radiopaque materials such as MP35N (ASTM 562), L-605 cobalt chromium (ASTM F90), other suitable alloys containing radiopaque elements, or multilayered materials having radiopaque layers. As a further option, the stent structures may have a geometry conducive to fluoroscopic visualization, such as having struts of greater thickness, sections of higher density, or overlapping struts. Some of the possible materials that may be used in the stent segments, either alone or in combination, include (by ASTM number):
The preferred embodiments of the invention are described above in detail for the purpose of setting forth a complete disclosure and for the sake of explanation and clarity. Those skilled in the art will envision other modifications within the scope and sprit of the present disclosure.
This application is a divisional of U.S. patent application Ser. No. 12/492,828 filed Jun. 26, 2009 which is a continuation of U.S. patent application Ser. No. 10/738,666 filed Dec. 16, 2003 which claims the priority benefit of U.S. Provisional Patent Application No. 60/440,839, filed Jan. 17, 2003, each of which the entire contents are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4069825 | Akiyama | Jan 1978 | A |
4468224 | Enzmann et al. | Aug 1984 | A |
4512338 | Balko | Apr 1985 | A |
4564014 | Fogarty et al. | Jan 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4681110 | Wiktor | Jul 1987 | A |
4690684 | McGreevy et al. | Sep 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4748982 | Horzewski et al. | Jun 1988 | A |
4762129 | Bonzel | Aug 1988 | A |
4770176 | McGreevy et al. | Sep 1988 | A |
4775337 | Van Wagener et al. | Oct 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4886062 | Wiktor | Dec 1989 | A |
4891225 | Langer et al. | Jan 1990 | A |
4950227 | Savin et al. | Aug 1990 | A |
4988356 | Crittenden et al. | Jan 1991 | A |
4994066 | Voss | Feb 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
4994298 | Yasuda | Feb 1991 | A |
5013318 | Spranza, III | May 1991 | A |
5035706 | Giantureo et al. | Jul 1991 | A |
5040548 | Yock | Aug 1991 | A |
5061273 | Yock | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5092877 | Pinchuk | Mar 1992 | A |
5102417 | Palmaz | Apr 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5135535 | Kramer | Aug 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5192297 | Hull | Mar 1993 | A |
5195984 | Schatz | Mar 1993 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5217495 | Kaplan et al. | Jun 1993 | A |
5219355 | Parodi et al. | Jun 1993 | A |
5226913 | Pinchuk | Jul 1993 | A |
5246421 | Saab | Sep 1993 | A |
5273536 | Savas | Dec 1993 | A |
5282824 | Gianturco | Feb 1994 | A |
5300085 | Yock | Apr 1994 | A |
5312415 | Palermo | May 1994 | A |
5328469 | Coletti | Jul 1994 | A |
5334187 | Fischell et al. | Aug 1994 | A |
5391172 | Williams et al. | Feb 1995 | A |
5421955 | Lau et al. | Jun 1995 | A |
5443498 | Fontaine | Aug 1995 | A |
5445646 | Euteneuer et al. | Aug 1995 | A |
5456713 | Chuter | Oct 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5470315 | Adams | Nov 1995 | A |
5478349 | Nicholas | Dec 1995 | A |
5490837 | Blaeser et al. | Feb 1996 | A |
5496346 | Horzewski et al. | Mar 1996 | A |
5501227 | Yock | Mar 1996 | A |
5507768 | Lau et al. | Apr 1996 | A |
5507771 | Gianturco | Apr 1996 | A |
5514093 | Ellis et al. | May 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5527354 | Fontaine et al. | Jun 1996 | A |
5531735 | Thompson | Jul 1996 | A |
5533968 | Muni et al. | Jul 1996 | A |
5534007 | St. Germain et al. | Jul 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5549551 | Peacock, III et al. | Aug 1996 | A |
5549563 | Kronner | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5554181 | Das | Sep 1996 | A |
5562725 | Schmitt et al. | Oct 1996 | A |
5571086 | Kaplan | Nov 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5593412 | Martinez et al. | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5628755 | Heller et al. | May 1997 | A |
5628775 | Jackson et al. | May 1997 | A |
5634928 | Fischell et al. | Jun 1997 | A |
5639274 | Fischell et al. | Jun 1997 | A |
5662675 | Polanskyj Stockert et al. | Sep 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5670161 | Healy et al. | Sep 1997 | A |
5676654 | Ellis et al. | Oct 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5697948 | Marin | Dec 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5702419 | Berry et al. | Dec 1997 | A |
5709701 | Parodi | Jan 1998 | A |
5716393 | Lindenberg et al. | Feb 1998 | A |
5722669 | Shimizu et al. | Mar 1998 | A |
5723003 | Winston et al. | Mar 1998 | A |
5735869 | Fernandez-Aceytuno | Apr 1998 | A |
5741323 | Pathak et al. | Apr 1998 | A |
5749848 | Jang et al. | May 1998 | A |
5749921 | Lenker et al. | May 1998 | A |
5755772 | Evans et al. | May 1998 | A |
5755776 | Al-Saadon | May 1998 | A |
5755781 | Jayaraman | May 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5772669 | Vrba | Jun 1998 | A |
5776141 | Klein et al. | Jul 1998 | A |
5792144 | Fischell et al. | Aug 1998 | A |
5797951 | Mueller et al. | Aug 1998 | A |
5800519 | Sandock | Sep 1998 | A |
5807398 | Shaknovich | Sep 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5833694 | Poncet | Nov 1998 | A |
5836964 | Richter et al. | Nov 1998 | A |
5843092 | Heller et al. | Dec 1998 | A |
5855563 | Kaplan et al. | Jan 1999 | A |
5858556 | Eckert et al. | Jan 1999 | A |
5870381 | Kawasaki et al. | Feb 1999 | A |
5879370 | Fischell et al. | Mar 1999 | A |
5891190 | Boneau | Apr 1999 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5899935 | Ding | May 1999 | A |
5902332 | Schatz | May 1999 | A |
5919175 | Sirhan | Jul 1999 | A |
5921971 | Agro et al. | Jul 1999 | A |
5922020 | Klein et al. | Jul 1999 | A |
5941869 | Patterson et al. | Aug 1999 | A |
5951585 | Cathcart et al. | Sep 1999 | A |
5961536 | Mickley et al. | Oct 1999 | A |
5968069 | Dusbabek et al. | Oct 1999 | A |
5972027 | Johnson | Oct 1999 | A |
5976107 | Mertens et al. | Nov 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
5980484 | Ressemann et al. | Nov 1999 | A |
5980486 | Enger | Nov 1999 | A |
5980514 | Kupiecki et al. | Nov 1999 | A |
5980552 | Pinchasik | Nov 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
5989280 | Euteneuer et al. | Nov 1999 | A |
5993484 | Shmulewitz | Nov 1999 | A |
5997563 | Kretzers et al. | Dec 1999 | A |
6004328 | Solar | Dec 1999 | A |
6007517 | Anderson | Dec 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6022359 | Frantzen | Feb 2000 | A |
6022374 | Imran | Feb 2000 | A |
6027519 | Stanford | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6036725 | Avellanet | Mar 2000 | A |
6039721 | Johnson et al. | Mar 2000 | A |
6042589 | Marianne | Mar 2000 | A |
6056722 | Jayaraman | May 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6066155 | Amann et al. | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6070589 | Keith et al. | Jun 2000 | A |
6090063 | Makower et al. | Jul 2000 | A |
6090136 | McDonald et al. | Jul 2000 | A |
6102942 | Ahari | Aug 2000 | A |
6106530 | Harada | Aug 2000 | A |
RE36857 | Euteneuer et al. | Sep 2000 | E |
6120522 | Vrba et al. | Sep 2000 | A |
6123712 | Di Caprio et al. | Sep 2000 | A |
6123723 | Konya et al. | Sep 2000 | A |
6126685 | Lenker et al. | Oct 2000 | A |
6129756 | Kugler | Oct 2000 | A |
6132460 | Thompson | Oct 2000 | A |
6139572 | Campbell et al. | Oct 2000 | A |
6143016 | Bleam et al. | Nov 2000 | A |
6165167 | Delaloye | Dec 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6171334 | Cox | Jan 2001 | B1 |
6179878 | Duering | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6187034 | Frantzen | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6196995 | Fagan | Mar 2001 | B1 |
6200337 | Moriuchi et al. | Mar 2001 | B1 |
6217585 | Houser et al. | Apr 2001 | B1 |
6238991 | Suzuki | May 2001 | B1 |
6241691 | Ferrera et al. | Jun 2001 | B1 |
6241758 | Cox | Jun 2001 | B1 |
6248122 | Klumb et al. | Jun 2001 | B1 |
6251132 | Ravenscroft et al. | Jun 2001 | B1 |
6251134 | Alt et al. | Jun 2001 | B1 |
6254612 | Hieshima | Jul 2001 | B1 |
6254628 | Wallace et al. | Jul 2001 | B1 |
6258117 | Camrud | Jul 2001 | B1 |
6264688 | Herklotz et al. | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6273895 | Pinchuk et al. | Aug 2001 | B1 |
6273911 | Cox et al. | Aug 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6287291 | Bigus et al. | Sep 2001 | B1 |
6312458 | Golds | Nov 2001 | B1 |
6315794 | Richter | Nov 2001 | B1 |
6319277 | Rudnick et al. | Nov 2001 | B1 |
6322586 | Monroe et al. | Nov 2001 | B1 |
6325823 | Horzewski et al. | Dec 2001 | B1 |
6334871 | Dor et al. | Jan 2002 | B1 |
6340366 | Wijay | Jan 2002 | B2 |
6344272 | Oldenburg et al. | Feb 2002 | B1 |
6348065 | Brown et al. | Feb 2002 | B1 |
6350252 | Ray et al. | Feb 2002 | B2 |
6350277 | Kocur | Feb 2002 | B1 |
6357104 | Myers | Mar 2002 | B1 |
6361558 | Hieshima et al. | Mar 2002 | B1 |
6375676 | Cox | Apr 2002 | B1 |
6379365 | Diaz | Apr 2002 | B1 |
6383171 | Gifford et al. | May 2002 | B1 |
6409753 | Brown et al. | Jun 2002 | B1 |
6415696 | Erickson et al. | Jul 2002 | B1 |
6416543 | Hilaire et al. | Jul 2002 | B1 |
6419693 | Fariabi | Jul 2002 | B1 |
6425898 | Wilson et al. | Jul 2002 | B1 |
6428811 | West et al. | Aug 2002 | B1 |
6451025 | Jervis | Sep 2002 | B1 |
6451050 | Rudakov et al. | Sep 2002 | B1 |
6464720 | Boatman et al. | Oct 2002 | B2 |
6468298 | Pelton | Oct 2002 | B1 |
6468299 | Stack et al. | Oct 2002 | B2 |
6485510 | Camrud et al. | Nov 2002 | B1 |
6488694 | Lau et al. | Dec 2002 | B1 |
6488702 | Besselink | Dec 2002 | B1 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6520986 | Martin et al. | Feb 2003 | B2 |
6520987 | Plante | Feb 2003 | B1 |
6527789 | Lau et al. | Mar 2003 | B1 |
6527799 | Shanley | Mar 2003 | B2 |
6530944 | West et al. | Mar 2003 | B2 |
6540777 | Stenzel | Apr 2003 | B2 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6555157 | Hossainy | Apr 2003 | B1 |
6558415 | Thompson | May 2003 | B2 |
6562067 | Mathis | May 2003 | B2 |
6569180 | Sirhan et al. | May 2003 | B1 |
6575993 | Yock | Jun 2003 | B1 |
6579305 | Lashinski | Jun 2003 | B1 |
6579309 | Loos et al. | Jun 2003 | B1 |
6582394 | Reiss et al. | Jun 2003 | B1 |
6582460 | Cryer | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589273 | McDermott | Jul 2003 | B1 |
6592549 | Gerdts et al. | Jul 2003 | B2 |
6599296 | Gillick et al. | Jul 2003 | B1 |
6599314 | Mathis | Jul 2003 | B2 |
6602226 | Smith et al. | Aug 2003 | B1 |
6602282 | Yan | Aug 2003 | B1 |
6605062 | Hurley et al. | Aug 2003 | B1 |
6605109 | Fiedler | Aug 2003 | B2 |
6607553 | Healy et al. | Aug 2003 | B1 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6629992 | Bigus et al. | Oct 2003 | B2 |
6645517 | West | Nov 2003 | B2 |
6645547 | Shekalim et al. | Nov 2003 | B1 |
6656212 | Ravenscroft et al. | Dec 2003 | B2 |
6660031 | Tran et al. | Dec 2003 | B2 |
6660381 | Halas et al. | Dec 2003 | B2 |
6663660 | Dusbabek et al. | Dec 2003 | B2 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6676693 | Belding et al. | Jan 2004 | B1 |
6676695 | Solem | Jan 2004 | B2 |
6679909 | McIntosh et al. | Jan 2004 | B2 |
6685730 | West et al. | Feb 2004 | B2 |
6692465 | Kramer | Feb 2004 | B2 |
6699280 | Camrud et al. | Mar 2004 | B2 |
6699281 | Vallana et al. | Mar 2004 | B2 |
6699724 | West et al. | Mar 2004 | B1 |
6702843 | Brown | Mar 2004 | B1 |
6709379 | Brandau et al. | Mar 2004 | B1 |
6709440 | Callol et al. | Mar 2004 | B2 |
6712827 | Ellis et al. | Mar 2004 | B2 |
6712845 | Hossainy | Mar 2004 | B2 |
6723071 | Gerdts et al. | Apr 2004 | B2 |
6736842 | Healy et al. | May 2004 | B2 |
6743219 | Dwyer et al. | Jun 2004 | B1 |
6743251 | Eder | Jun 2004 | B1 |
6761734 | Suhr | Jul 2004 | B2 |
6776771 | Van Moorlegem et al. | Aug 2004 | B2 |
6778316 | Halas et al. | Aug 2004 | B2 |
6790227 | Burgermeister | Sep 2004 | B2 |
6800065 | Duane et al. | Oct 2004 | B2 |
6825203 | Pasternak et al. | Nov 2004 | B2 |
6837901 | Rabkin et al. | Jan 2005 | B2 |
6849084 | Rabkin et al. | Feb 2005 | B2 |
6852252 | Halas et al. | Feb 2005 | B2 |
6855125 | Shanley | Feb 2005 | B2 |
6858034 | Hijlkema et al. | Feb 2005 | B1 |
6878161 | Lenker | Apr 2005 | B2 |
6884257 | Cox | Apr 2005 | B1 |
6893417 | Gribbons et al. | May 2005 | B2 |
6896695 | Mueller et al. | May 2005 | B2 |
6899728 | Phillips et al. | May 2005 | B1 |
6913619 | Brown et al. | Jul 2005 | B2 |
6918928 | Wolinsky et al. | Jul 2005 | B2 |
6939376 | Shulz et al. | Sep 2005 | B2 |
6945989 | Betelia et al. | Sep 2005 | B1 |
6945995 | Nicholas | Sep 2005 | B2 |
6951053 | Padilla et al. | Oct 2005 | B2 |
6962603 | Brown et al. | Nov 2005 | B1 |
6964676 | Gerberding et al. | Nov 2005 | B1 |
6991646 | Clerc et al. | Jan 2006 | B2 |
6994721 | Israel | Feb 2006 | B2 |
7005454 | Brocchini et al. | Feb 2006 | B2 |
7022132 | Kocur | Apr 2006 | B2 |
7029493 | Majercak et al. | Apr 2006 | B2 |
7037327 | Salmon et al. | May 2006 | B2 |
7090694 | Morris et al. | Aug 2006 | B1 |
7101840 | Brocchini et al. | Sep 2006 | B2 |
7131993 | Gregorich | Nov 2006 | B2 |
7137993 | Acosta et al. | Nov 2006 | B2 |
7141063 | White et al. | Nov 2006 | B2 |
7147655 | Chermoni | Dec 2006 | B2 |
7147656 | Andreas et al. | Dec 2006 | B2 |
7169172 | Levine et al. | Jan 2007 | B2 |
7169174 | Fischell et al. | Jan 2007 | B2 |
7172620 | Gilson | Feb 2007 | B2 |
7175654 | Bonsignore et al. | Feb 2007 | B2 |
7182779 | Acosta et al. | Feb 2007 | B2 |
7192440 | Andreas et al. | Mar 2007 | B2 |
7208001 | Coyle et al. | Apr 2007 | B2 |
7220275 | Davidson et al. | May 2007 | B2 |
7220755 | Betts et al. | May 2007 | B2 |
7223283 | Chouinard | May 2007 | B2 |
7238197 | Sequin et al. | Jul 2007 | B2 |
7241308 | Andreas et al. | Jul 2007 | B2 |
7244336 | Fischer et al. | Jul 2007 | B2 |
7270668 | Andreas et al. | Sep 2007 | B2 |
7294146 | Chew et al. | Nov 2007 | B2 |
7300456 | Andreas et al. | Nov 2007 | B2 |
7309350 | Landreville et al. | Dec 2007 | B2 |
7314480 | Eidenschink et al. | Jan 2008 | B2 |
7320702 | Hammersmark et al. | Jan 2008 | B2 |
7323006 | Andreas et al. | Jan 2008 | B2 |
7326236 | Andreas et al. | Feb 2008 | B2 |
7351255 | Andreas | Apr 2008 | B2 |
7918881 | Andreas et al. | Apr 2011 | B2 |
7993388 | Lee et al. | Aug 2011 | B2 |
8282680 | Kao et al. | Oct 2012 | B2 |
8317850 | Kusleika | Nov 2012 | B2 |
20010020154 | Bigus et al. | Sep 2001 | A1 |
20010020173 | Klumb et al. | Sep 2001 | A1 |
20010020181 | Layne | Sep 2001 | A1 |
20010035902 | Iddan et al. | Nov 2001 | A1 |
20010044595 | Reydel et al. | Nov 2001 | A1 |
20010044632 | Daniel et al. | Nov 2001 | A1 |
20010049547 | Moore | Dec 2001 | A1 |
20020007212 | Brown et al. | Jan 2002 | A1 |
20020035395 | Sugimoto | Mar 2002 | A1 |
20020037358 | Barry et al. | Mar 2002 | A1 |
20020045914 | Roberts et al. | Apr 2002 | A1 |
20020052642 | Cox et al. | May 2002 | A1 |
20020091439 | Baker et al. | Jul 2002 | A1 |
20020092536 | LaFontaine et al. | Jul 2002 | A1 |
20020107560 | Richter | Aug 2002 | A1 |
20020111671 | Stenzel | Aug 2002 | A1 |
20020123786 | Gittings et al. | Sep 2002 | A1 |
20020128706 | Ospyka | Sep 2002 | A1 |
20020138132 | Brown | Sep 2002 | A1 |
20020151924 | Shiber | Oct 2002 | A1 |
20020151955 | Tran et al. | Oct 2002 | A1 |
20020156496 | Chermoni | Oct 2002 | A1 |
20020165599 | Nasralla | Nov 2002 | A1 |
20020168317 | Daighighian et al. | Nov 2002 | A1 |
20020177890 | Lenker | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020188343 | Mathis | Dec 2002 | A1 |
20020188347 | Mathis | Dec 2002 | A1 |
20020193873 | Brucker et al. | Dec 2002 | A1 |
20030045923 | Bashiri et al. | Mar 2003 | A1 |
20030093143 | Zhao et al. | May 2003 | A1 |
20030097169 | Brucker et al. | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030114919 | McQuiston et al. | Jun 2003 | A1 |
20030114922 | Iwasaka et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125800 | Shulze et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030135266 | Chew et al. | Jul 2003 | A1 |
20030139796 | Sequin et al. | Jul 2003 | A1 |
20030139797 | Johnson et al. | Jul 2003 | A1 |
20030139798 | Brown et al. | Jul 2003 | A1 |
20030163085 | Tanner et al. | Aug 2003 | A1 |
20030176909 | Kusleika | Sep 2003 | A1 |
20030191516 | Weldon et al. | Oct 2003 | A1 |
20030195609 | Berenstein | Oct 2003 | A1 |
20030199821 | Gerdts et al. | Oct 2003 | A1 |
20030204238 | Tedeschi | Oct 2003 | A1 |
20030208223 | Kleiner | Nov 2003 | A1 |
20030212447 | Euteneuer | Nov 2003 | A1 |
20030225446 | Hartley | Dec 2003 | A1 |
20040015224 | Armstrong et al. | Jan 2004 | A1 |
20040024450 | Shulze et al. | Feb 2004 | A1 |
20040030380 | Shulze et al. | Feb 2004 | A1 |
20040044395 | Nelson | Mar 2004 | A1 |
20040073290 | Chouinard | Apr 2004 | A1 |
20040088044 | Brown et al. | May 2004 | A1 |
20040093061 | Acosta et al. | May 2004 | A1 |
20040093067 | Israel | May 2004 | A1 |
20040098081 | Landreville et al. | May 2004 | A1 |
20040106979 | Goicoechea | Jun 2004 | A1 |
20040111145 | Serino et al. | Jun 2004 | A1 |
20040117008 | Wnendt et al. | Jun 2004 | A1 |
20040143322 | Litvack et al. | Jul 2004 | A1 |
20040176832 | Hartley et al. | Sep 2004 | A1 |
20040181239 | Dorn et al. | Sep 2004 | A1 |
20040186551 | Kao et al. | Sep 2004 | A1 |
20040193245 | Deem et al. | Sep 2004 | A1 |
20040215165 | Coyle et al. | Oct 2004 | A1 |
20040215312 | Andreas et al. | Oct 2004 | A1 |
20040215331 | Chew et al. | Oct 2004 | A1 |
20040230285 | Gifford, III et al. | Nov 2004 | A1 |
20040243217 | Andersen et al. | Dec 2004 | A1 |
20040249434 | Andreas et al. | Dec 2004 | A1 |
20040249439 | Richter et al. | Dec 2004 | A1 |
20050004657 | Burgermeister | Jan 2005 | A1 |
20050010276 | Acosta et al. | Jan 2005 | A1 |
20050038494 | Eidenschink | Feb 2005 | A1 |
20050038505 | Shulze et al. | Feb 2005 | A1 |
20050049673 | Andreas et al. | Mar 2005 | A1 |
20050080474 | Andreas et al. | Apr 2005 | A1 |
20050080475 | Andreas et al. | Apr 2005 | A1 |
20050090846 | Pedersen et al. | Apr 2005 | A1 |
20050123451 | Nomura | Jun 2005 | A1 |
20050125051 | Eidenschink et al. | Jun 2005 | A1 |
20050131008 | Betts et al. | Jun 2005 | A1 |
20050137622 | Griffin | Jun 2005 | A1 |
20050143827 | Globerman et al. | Jun 2005 | A1 |
20050149168 | Gregorich | Jul 2005 | A1 |
20050165378 | Heinrich et al. | Jul 2005 | A1 |
20050182477 | White | Aug 2005 | A1 |
20050209674 | Kutscher et al. | Sep 2005 | A1 |
20050222671 | Schaeffer et al. | Oct 2005 | A1 |
20050228477 | Grainger et al. | Oct 2005 | A1 |
20050245637 | Hossainy et al. | Nov 2005 | A1 |
20050249777 | Michal et al. | Nov 2005 | A1 |
20050278011 | Peckham | Dec 2005 | A1 |
20050288764 | Snow et al. | Dec 2005 | A1 |
20050288766 | Plain et al. | Dec 2005 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060173529 | Blank | Aug 2006 | A1 |
20060200223 | Andreas et al. | Sep 2006 | A1 |
20060206190 | Chermoni | Sep 2006 | A1 |
20060229700 | Acosta et al. | Oct 2006 | A1 |
20060229706 | Shulze et al. | Oct 2006 | A1 |
20060271150 | Andreas et al. | Nov 2006 | A1 |
20060271151 | McGarry et al. | Nov 2006 | A1 |
20060282147 | Andreas | Dec 2006 | A1 |
20060282149 | Kao | Dec 2006 | A1 |
20060282150 | Olson et al. | Dec 2006 | A1 |
20060287726 | Segal et al. | Dec 2006 | A1 |
20070010869 | Sano | Jan 2007 | A1 |
20070027521 | Andreas et al. | Feb 2007 | A1 |
20070043419 | Nikolchev et al. | Feb 2007 | A1 |
20070067012 | George et al. | Mar 2007 | A1 |
20070088368 | Acosta et al. | Apr 2007 | A1 |
20070088420 | Andreas et al. | Apr 2007 | A1 |
20070088422 | Chew et al. | Apr 2007 | A1 |
20070100423 | Acosta et al. | May 2007 | A1 |
20070100424 | Chew et al. | May 2007 | A1 |
20070106365 | Andreas et al. | May 2007 | A1 |
20070118202 | Chermoni | May 2007 | A1 |
20070118203 | Chermoni | May 2007 | A1 |
20070118204 | Chermoni | May 2007 | A1 |
20070129733 | Will et al. | Jun 2007 | A1 |
20070135906 | Badylak et al. | Jun 2007 | A1 |
20070156225 | George et al. | Jul 2007 | A1 |
20070156226 | Chew et al. | Jul 2007 | A1 |
20070179587 | Acosta et al. | Aug 2007 | A1 |
20070219612 | Andreas et al. | Sep 2007 | A1 |
20070219613 | Kao et al. | Sep 2007 | A1 |
20070265637 | Andreas et al. | Nov 2007 | A1 |
20070270936 | Andreas et al. | Nov 2007 | A1 |
20070276461 | Andreas et al. | Nov 2007 | A1 |
20070281117 | Kaplan et al. | Dec 2007 | A1 |
20070292518 | Ludwig | Dec 2007 | A1 |
20080004690 | Robaina | Jan 2008 | A1 |
20080046067 | Toyokawa | Feb 2008 | A1 |
20080071345 | Hammersmark et al. | Mar 2008 | A1 |
20080077229 | Andreas et al. | Mar 2008 | A1 |
20080091257 | Andreas et al. | Apr 2008 | A1 |
20080097299 | Andreas et al. | Apr 2008 | A1 |
20080097574 | Andreas et al. | Apr 2008 | A1 |
20080125850 | Andreas et al. | May 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080147162 | Andreas et al. | Jun 2008 | A1 |
20080177369 | Will et al. | Jul 2008 | A1 |
20080199510 | Ruane et al. | Aug 2008 | A1 |
20080208311 | Kao et al. | Aug 2008 | A1 |
20080208318 | Kao et al. | Aug 2008 | A1 |
20080234795 | Snow et al. | Sep 2008 | A1 |
20080234798 | Chew et al. | Sep 2008 | A1 |
20080234799 | Acosta et al. | Sep 2008 | A1 |
20080243225 | Satasiya et al. | Oct 2008 | A1 |
20080249607 | Webster et al. | Oct 2008 | A1 |
20080269865 | Snow et al. | Oct 2008 | A1 |
20090076584 | Mao et al. | Mar 2009 | A1 |
20090105686 | Snow et al. | Apr 2009 | A1 |
20090149863 | Andreas et al. | Jun 2009 | A1 |
20090234428 | Snow et al. | Sep 2009 | A1 |
20090248137 | Andersen et al. | Oct 2009 | A1 |
20090248140 | Gerberding | Oct 2009 | A1 |
20090276030 | Kusleika | Nov 2009 | A1 |
20100004729 | Chew et al. | Jan 2010 | A1 |
Number | Date | Country |
---|---|---|
1 953 1659 | Mar 1997 | DE |
1 963 0469 | Jan 1998 | DE |
199 50 756 | Aug 2000 | DE |
101 03 000 | Aug 2002 | DE |
0 203 945 | Dec 1986 | EP |
0 274 129 | Jul 1988 | EP |
0 282 143 | Sep 1988 | EP |
0 364 787 | Apr 1990 | EP |
0 505 686 | Sep 1992 | EP |
0 533 960 | Mar 1993 | EP |
0 596 145 | May 1994 | EP |
0 696 447 | Feb 1996 | EP |
0 714 640 | Jun 1996 | EP |
0 797 963 | Jan 1997 | EP |
0 947 180 | Oct 1999 | EP |
1 258 230 | Nov 2002 | EP |
1 266 638 | Dec 2002 | EP |
1 277 449 | Jan 2003 | EP |
1 290 987 | Mar 2003 | EP |
1 318 765 | Jun 2003 | EP |
1 523 959 | Apr 2005 | EP |
1 523 960 | Apr 2005 | EP |
2277875 | Nov 1994 | GB |
03-133446 | Jun 1991 | JP |
07-132148 | May 1995 | JP |
10-503663 | Apr 1998 | JP |
10-295823 | Nov 1998 | JP |
2001-190687 | Jul 2001 | JP |
2002-538932 | Nov 2002 | JP |
2004-121343 | Apr 2004 | JP |
9427667 | Dec 1994 | WO |
9526695 | Oct 1995 | WO |
9529647 | Nov 1995 | WO |
9626689 | Sep 1996 | WO |
9633677 | Oct 1996 | WO |
9637167 | Nov 1996 | WO |
9639077 | Dec 1996 | WO |
9710778 | Mar 1997 | WO |
9746174 | Dec 1997 | WO |
9748351 | Dec 1997 | WO |
9820810 | May 1998 | WO |
9837833 | Sep 1998 | WO |
9858600 | Dec 1998 | WO |
9901087 | Jan 1999 | WO |
9965421 | Dec 1999 | WO |
0012832 | Mar 2000 | WO |
0015151 | Mar 2000 | WO |
0025841 | May 2000 | WO |
0032136 | Jun 2000 | WO |
0041649 | Jul 2000 | WO |
0050116 | Aug 2000 | WO |
0051525 | Sep 2000 | WO |
0056237 | Sep 2000 | WO |
0062708 | Oct 2000 | WO |
0072780 | Dec 2000 | WO |
0126707 | Apr 2001 | WO |
0134063 | May 2001 | WO |
0170297 | Sep 2001 | WO |
0191918 | Dec 2001 | WO |
02060344 | Aug 2002 | WO |
02085253 | Oct 2002 | WO |
02098326 | Dec 2002 | WO |
03022178 | Mar 2003 | WO |
03047651 | Jun 2003 | WO |
03051425 | Jun 2003 | WO |
03075797 | Sep 2003 | WO |
2004017865 | Mar 2004 | WO |
2004043299 | May 2004 | WO |
2004043301 | May 2004 | WO |
2004043510 | May 2004 | WO |
2004052237 | Jun 2004 | WO |
2004087006 | Oct 2004 | WO |
2004091441 | Oct 2004 | WO |
2005009295 | Feb 2005 | WO |
2005013853 | Feb 2005 | WO |
2005023153 | Mar 2005 | WO |
2006036939 | Apr 2006 | WO |
2006047520 | May 2006 | WO |
2007035805 | Mar 2007 | WO |
2007053187 | May 2007 | WO |
2007146411 | Dec 2007 | WO |
2008005111 | Jan 2008 | WO |
Entry |
---|
Chu et al., “Preparation of Thermo-Responsive Core-Shell Microcapsules with a Porous Membrane and Poly(N-isopropylacrylamide) Gates,” J Membrane Sci, Oct. 15, 2001; 192(1-2):27-39. |
Colombo, “The Invatec Bifurcation Stent Solution” Bifurcation Stents: Novel Solutions, TCT 2003, Washington: Sep. 15-19, 2003, 24 pages total. |
Cooley et al., “Applications of Ink-Jet Printing Technology to BioMEMs and Microfluidic Systems,” Proceedings, SPIE Conference on Microfluidics and BioMEMs, (Oct. 2001). |
“Drug Delivery Stent With Holes Located on Neutral Axis” Research Disclosure, Kenneth Mason Publications, Hampshire, CB, No. 429, Jan. 2000, p. 13, XP00976354. |
Evans Analytical Group, “Functional Sites on Non-polymeric Materials: Gas Plasma Treatment and Surface Analysis,” http://www.eaglabs.com. |
Joung et al., “Estrogen Release from Metallic Stent Surface for the Prevention of Restenosis,” Journal of Controlled Release 92 (2003) pp. 83-91. |
Lefevre et al. “Approach to Coronary Bifurcation Stenting in 2003,” Euro PCR, (May 2003) 28 pages total. |
“STENT”. Definitions from Dictionary.com. Unabridged 9v1.01). Retrieved Sep. 22, 2006, from Dictionary.com website: <http://dictionary.reference.com/search?q=stent>. |
Stimpson et al., Parallel Production of Oligonucleotide Arrays Using Membranes and Reagent Jet Printing, BioTechniques 25:886-890 (Nov. 1998). |
Tilley , “Biolimus A9-Eluting Stent Shows Promise,” Medscape Medical News, Oct. 5, 2004; retrieved from the internet: <http://www.medscape.com/viewarticle/490621>, 2 pages total. |
Weir et al., “Degradation of poly-L-lactide. Part 2: increased temperature accelerated degradation,” Proc Inst Mech Eng H. 2004;218(5):321-30. |
International Search Report of PCT/US2002/038810, dated Apr. 1, 2003, 1 page. |
International Search Report of PCT/US2002/038845, dated Mar. 2003, 2 pages. |
Supplementary European Search Report of EP Patent Application No. 02804509, dated Dec. 13, 2006, 1 page total. |
Supplementary European Search Report of EP Patent Application No. 04749567, dated Sep. 11, 2006, 3 pages total. |
Supplementary European Search Report of EP Patent Application No. 05727731.1, dated Mar. 25, 2008, 2 pages total. |
Supplementary European Search Report of EP Patent Application No. 05744136, dated Mar. 26, 2008, 3 pages total. |
U.S. Appl. No. 60/336,607, filed Dec. 3, 2001, first named inventor: Bernard Andreas. |
U.S. Appl. No. 60/336,767, filed Dec. 3, 2001, first named inventor: Bernard Andreas. |
U.S. Appl. No. 60/336,967, filed Dec. 3, 2001, first named inventor: Sunmi Chew. |
U.S. Appl. No. 60/364,389, filed Mar. 13, 2002, first named inventor: Sunmi Chew. |
U.S. Appl. No. 60/440,839, filed Jan. 17, 2003, first named inventor: Bernard Andreas. |
U.S. Appl. No. 60/561,041, filed Apr. 9, 2004, first named inventor: Jeffry Grainger. |
U.S. Appl. No. 60/784,309, filed Mar. 20, 2006, first named inventor: Bernard Andreas. |
U.S. Appl. No. 60/810,522, filed Jun. 2, 2006, first named inventor: Stephen Kaplan. |
U.S. Appl. No. 60/890,703, filed Feb. 20, 2007, first named inventor: Patrick Ruane. |
U.S. Appl. No. 61/012,317, filed Dec. 7, 2007, first named inventor: Patrick Ruane. |
U.S. Appl. No. 09/097,855, filed Jun. 15, 1998, first named inventor: Enrique J. Klein; Abandoned. |
U.S. Appl. No. 09/225,364, filed Jan. 4, 1999, first named inventor: Aaron V. Kaplan; Abandoned. |
U.S. Appl. No. 10/874,859, filed Jun. 22, 2004, first named inventor: Pablo Acosta.; Abandoned. |
U.S. Appl. No. 11/462,951, filed Aug. 7, 2006, first named inventor: David Snow. |
U.S. Appl. No. 11/627,096, filed Jan. 25, 2007, first named inventor: Bernard Andreas. |
U.S. Appl. No. 11/689,927, filed Mar. 22, 2007, first named inventor: David Snow. |
U.S. Appl. No. 11/771,929, filed Jun. 29, 2007, first named inventor: David Snow. |
U.S. Appl. No. 11/857,562, filed Sep. 19, 2007, first named inventor: Bryan Mao. |
U.S. Appl. No. 11/938,730, filed Nov. 12, 2007, first named inventor: Sunmi Chew. |
U.S. Appl. No. 11/945,142, filed Nov. 26, 2007, first named inventor: Bernard Andreas. |
U.S. Appl. No. 11/947,677, filed Nov. 29, 2007, first named inventor: Dan Hammersmark. |
U.S. Appl. No. 11/952,644, filed Dec. 7, 2007, first named inventor: Bernard Andreas. |
U.S. Appl. No. 12/033,586, filed Feb. 19, 2008, first named inventor: Patrick H. Ruane. |
U.S. Appl. No. 12/043,513, filed Mar. 6, 2008, first named inventor: David Lowe. |
U.S. Appl. No. 12/040,598, filed Feb. 29, 2008, first named inventor: Bernard Andreas. |
U.S. Appl. No. 12/057,527, filed Mar. 28, 2008, first named inventor: Allan Will. |
U.S. Appl. No. 12/061,951, filed Apr. 3, 2008, first named inventor: Stephen Kao. |
U.S. Appl. No. 12/109,477, filed Apr. 25, 2008, first named inventor: Stephen Kao. |
U.S. Appl. No. 12/127,147, filed May 27, 2008, first named inventor: Sunmi Chew. |
U.S. Appl. No. 12/133,909, filed Jun. 5, 2008, first named inventor: David Sanderson. |
Number | Date | Country | |
---|---|---|---|
20130060321 A1 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
60440839 | Jan 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12492828 | Jun 2009 | US |
Child | 13599957 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10738666 | Dec 2003 | US |
Child | 12492828 | US |